Prosecution Insights
Last updated: April 19, 2026

Loxo Oncology Inc.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
1
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18555467 COCRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR RAHMANI, NILOOFAR 1691 Non-Final OA Oct 13, 2023
18043971 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE SEAMAN, D MARGARET M 1625 Non-Final OA Mar 03, 2023
18041617 OSIMERTINIB AND SELPERCATINIB COMBINATIONS FOR THE TREATMENT OF EGFR- AND RET-ASSOCIATED CANCERS BURKETT, DANIEL JOHN 1624 Non-Final OA Feb 14, 2023
17996028 CRYSTALLINE RET INHIBITOR MARTIN, KEVIN STEPHEN 1624 Final Rejection Oct 12, 2022

Managing Loxo Oncology Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month